Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Forte Biosciences Inc FBRX

Healthcare Biotechnology
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo... see more

Current News (NDAQ:FBRX)

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Business Wire November 24, 2025

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Business Wire November 14, 2025

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Business Wire November 3, 2025

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Business Wire October 3, 2025

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Business Wire September 15, 2025

Forte Biosciences, Inc. Announces Results and Provides Update

Business Wire August 14, 2025

Forte Biosciences Announces Pricing of $75 Million Public Offering

Business Wire June 25, 2025

Forte Biosciences Announces Proposed Public Offering

Business Wire June 24, 2025

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Business Wire June 23, 2025
View More News ››

Opinion & Analysis (NDAQ:FBRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:FBRX)

Using technical analysis for this stock.

This stock is signalling a big downswing for shareholders this morning anyway
coolfooldumbguy - June 25, 2025

$FBRX Advances, $MYNZ Steadies

$FBRX adds 2.3%, hitting $24.00 as market enthusiasm for its dermatological treatments grows. In the same biotech sphere, $MYNZ...
IronFocus77 - December 4, 2024

FBRX Rockets on $53M Cash Infusion

FBRX scored a $53M private placement, and the stock's on fire! This cash boost is set to fuel their autoimmune drug, FB102. Bulls are...
TradeVanguard27 - November 27, 2024

FBRX ...... Bad NR hit share price hard !!!!

Down a ton.....any gamblers out there? Currently trading at $5.31 Cheers !
Iseneschal - September 3, 2021
View more Bullboard ››

North Peak Resources Ltd.

North Peak Resources Ltd.

North Peak Resources Ltd. operates as a gold exploration and development company. The company’s flagship project is the ...
View More »